Toceranib
356068-94-5
0.98%
2026-07-11
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Product Description
-
Seller Information
-
Description
ProductName Toceranib Cat No CEI-1557 Description Toceranib is an inhibitor of receptor tyrosine kinases (RTKs). Product Overview Toceranib is an inhibitor which blocks various tyrosine kinases expressed on the cell surface. Receptor tyrosine kinases (RTKs) are excellent candidates for molecular targeted therapy, because they play key roles in controlling cell proliferation and survival and are frequently dysregulated in a variety of malignancies. CAS No 356068-94-5 Molecular Weight 396.46 Purity 0.98 Storage Store at -20°C Synonyms SU 11654; PHA 291639; SU11654; SU-11654; PHA-291639; PHA291639 Targets KIT; VEGFR2; PDGFR2 Molecular Formula C22H25FN4O2 Chemical Name 5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-pyrrolidin-1-ylethyl)-1H-pyrrole-3-carboxamide Solubility Limited solubility Shipping Conditions Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request In vitro Toceranib inhibited KIT phosphorylation and cell proliferation in a dose-dependent manner in the treatment-naïve, parental C2 line (IC50< 10 nM). In addition, chronic TOC exposure resulted in c-kit mRNA and KIT protein overexpression in the TOC-resistant sublines. In vivo Fourteen dogs with advanced mast cell tumors (MCTs) were enrolled in a prevoius study, among which 11 dogs were evaluable for KIT target modulation. Of these, eight MCTs showed reduced levels of phosphorylated KIT relative to total KIT after treatment with Toceranib, compared with pretreatment biopsies. All four evaluable MCTs expressing ITD mutant c-kit showed modulation of KIT phosphorylation, as did four of seven tumors expressing non-ITD c-kit. category Bulk Drug Intermediates(c1112) cas_num 356068-94-5 Basic Info-
Product Name:
Toceranib
Other Name:1H-Pyrrole-3-carboxamide,5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-;5-[(Z)-(5-Fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-1H-pyrrole-3-carboxamide;5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide;SU 11654;Toceranib;PHA 291639;Palladia
CAS No.:356068-94-5
Molecular Formula:C22H25FN4O2
InChIKeys:InChIKey=SRSGVKWWVXWSJT-ATVHPVEESA-N
Molecular Weight:396.46
Exact Mass:396.46
UNII:59L7Y0530C
DSSTox ID:DTXSID50189076
ATC Code:QL01EX90
Categories:
Characteristics-
PSA:
77.23000
XLogP3:3.55570
Density:1.293
Boiling Point:596.8±50.0 °C(Predicted)
PKA:11.70±0.20
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Location:
Shirley, New York 11967, USA
-
Payment Terms:
TT against copy of documents,D/P
-
Average lead Time:
15
-
Total Annual Revenue:
$1 million-$2.5 million
-
Year of Establishment:
2004
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product